BEAM
Price
$17.25
Change
+$1.02 (+6.28%)
Updated
May 8 closing price
Capitalization
1.63B
95 days until earnings call
NVAX
Price
$6.66
Change
+$0.71 (+11.93%)
Updated
May 8 closing price
Capitalization
963.71M
89 days until earnings call
Ad is loading...

BEAM vs NVAX

Header iconBEAM vs NVAX Comparison
Open Charts BEAM vs NVAXBanner chart's image
Beam Therapeutics
Price$17.25
Change+$1.02 (+6.28%)
Volume$3.15M
Capitalization1.63B
Novavax
Price$6.66
Change+$0.71 (+11.93%)
Volume$36.87M
Capitalization963.71M
BEAM vs NVAX Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. NVAX commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and NVAX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (BEAM: $17.25 vs. NVAX: $6.66)
Brand notoriety: BEAM: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 119% vs. NVAX: 594%
Market capitalization -- BEAM: $1.63B vs. NVAX: $963.71M
BEAM [@Biotechnology] is valued at $1.63B. NVAX’s [@Biotechnology] market capitalization is $963.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • NVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both BEAM and NVAX are a bad buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а -13.01% price change this week, while NVAX (@Biotechnology) price change was +3.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.63B) has a higher market cap than NVAX($964M). NVAX YTD gains are higher at: -17.164 vs. BEAM (-30.444). NVAX has higher annual earnings (EBITDA): -108.04M vs. BEAM (-383.98M). NVAX has more cash in the bank: 923M vs. BEAM (851M). BEAM has less debt than NVAX: BEAM (161M) vs NVAX (230M). NVAX has higher revenues than BEAM: NVAX (682M) vs BEAM (63.5M).
BEAMNVAXBEAM / NVAX
Capitalization1.63B964M169%
EBITDA-383.98M-108.04M355%
Gain YTD-30.444-17.164177%
P/E RatioN/AN/A-
Revenue63.5M682M9%
Total Cash851M923M92%
Total Debt161M230M70%
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
13
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMNVAX
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRNEX36.53N/A
N/A
T. Rowe Price New Era
HNVIX31.21N/A
N/A
Heartland Value Plus Institutional
AMLPX9.16N/A
N/A
MainGate MLP A
ECASX26.89N/A
N/A
Eaton Vance Atlanta Capital SMID-Cap C
FEMAX10.37N/A
N/A
First Eagle U.S. SMID Cap Opportunity A

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+6.32%
CRSP - BEAM
72%
Closely correlated
+5.52%
NTLA - BEAM
66%
Loosely correlated
+13.58%
RXRX - BEAM
63%
Loosely correlated
+4.77%
PRME - BEAM
59%
Loosely correlated
-7.04%
RCKT - BEAM
58%
Loosely correlated
+11.57%
More